A5069763572- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Lung Cancer Research Studies
- Axon Guidance and Neuronal Signaling
- Immunotherapy and Immune Responses
- Pharmaceutical studies and practices
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Surgical Treatments
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Radiopharmaceutical Chemistry and Applications
- Nonmelanoma Skin Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
University of Campania "Luigi Vanvitelli"
2020-2024
Adjuvant immunotherapy (IO) and targeted therapy (TT) have improved relapse-free survival (RFS) in patients with stage III melanoma, although about 25% of them relapse within a year. However, real-world data on treatment efficacy safety as well management recurrences are still limited. We retrospectively analyzed 113 melanoma who received at least one cycle anti-PD-1 (nivolumab or pembrolizumab) dabrafenib + trametinib adjuvant therapy. Most included into the analyses harbor BRAV600E...
Liquid biopsy is a potentially useful tool for melanoma patients, also detecting BRAS/NRAS mutations, even if the tissue analysis remains current standard.In this work, we tested ctDNA on plasma samples from 56 BRAF-V600/NRAS mutant stage III/IV patients using real-time quantitative PCR (qPCR)-based platform. The study population was divided into two cohorts: first including 26 who had undergone radical resection (resected cohort) and second 30 unresected measurable disease (advanced...
Mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) refer to heterogenous rare constituted of at least a population—either well-differentiated, or more frequently poorly differentiated—and population, both accounting for 30% the whole tumor mass. Several studies recently focused on key genetic and epigenetic changes underlying MiNENs better understand how they develop, explore biological similarities among two components their pure counterparts. However, molecular landscape still...
Cemiplimab has demonstrated relevant clinical activity in cutaneous squamous cell carcinoma (cSCC) but mechanisms of primary and acquired resistance to immunotherapy are still unknown. We collected data from locally advanced and/or metastatic cSSC patients treated with cemiplimab two Italian University centers. In addition, gene expression analysis by using Nanostring Technologies platform evaluate 770 cancer- immune-related genes on 20 tumor tissue samples (9 responders 11 non-responders...
The combination of trifluridine-tipiracil and bevacizumab was compared with monotherapy in a randomized, open-label, phase II trial, resulting statistically significant clinically relevant improvement progression-free survival (PFS), tolerable toxicity patients refractory metastatic colorectal cancer (mCRC); however, evidence supporting the role this real-world setting is limited. aim our work to provide further on activity safety series Western mCRC or intolerant previous therapies. We...
Abstract The BRAF and MEK inhibitors combined strategies have dramatically changed the outcome of BRAF-mutated metastatic melanoma patients. However, despite initial promising results, onset primary or acquired resistance occurs in nearly half patients at about one year from diagnosis. Understanding mechanisms to these is therefore critical for planning more effective therapeutic able improve patient outcomes. To this aim we generated resistant cells starting SAN A375 lines, both harboring...
•Metastatic colorectal cancer is one of the most common causes death worldwide.•Primary and acquired resistance mechanisms to anti-EGFR treatment are a challenging topic with several clinical implications.•Primary defined by presence activating mutations in BRAF RAS genes before initiation, while refers selection pre-existing mutant clones or de novo acquisition under pressure anti EGFR treatment.•Testing as predictive biomarkers mandatory.•Liquid biopsy has growing importance showed be...
Abstract The BRAF and MEK inhibitors combined strategies have dramatically changed the outcome of BRAF-mutated metastatic melanoma patients. However, despite initial promising results, onset primary or acquired resistance occurs in nearly half patients at about 1 year from diagnosis. Understanding mechanisms to these is therefore critical for planning more effective therapeutic able improve patient outcomes. To this aim we generated resistant cells starting SAN A375 lines, both harboring...